Global /China /Healthcare /Biotechnology /300676

BGI Genomics Co., Ltd.

300676

• SHE: 300676 • Delayed

39.94CNY -0.9%

5.90 USD

As of 15 June 2026, BGI Genomics Co., Ltd. has a market cap of $2.29B USD, ranking #6468 globally and #1507 in China. It ranks #512 in the Healthcare sector, and #96 in the Biotechnology industry.

Global Rank

6468

Country Rank

1507

Sector Rank

512

Industry Rank

Key Stats

Market Cap

$2.29BUSD

15.47B CNY

Enterprise Value

$1.89BUSD

12.82B CNY

Revenue (TTM)

$567.74MUSD

3.84B CNY

EBITDA (TTM)

-$7.9MUSD

-53.47M CNY

Net Income (TTM)

-$84.74MUSD

-573.48M CNY

EBITDA Margin

-1.4%

Profit Margin

-15%

PS Ratio

4.0

PB Ratio

1.8

Company Profile

Country (HQ)

China

Sector

Healthcare

Industry

Biotechnology

CEO

Lijian Zhao open_in_new

Employees

3,580

Founded

1999

Website

bgi.com open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
-0.9%	2.7%	0.3%	-23%	-17%	-11%	-16%	-35%	-69%

News

Markets

Exchange	Ticker	Price	Quotes
Shenzhen Stock Exchange (SHE / SZSE) MIC: XSHE PRIMARY	300676 深圳华大基因股份有限公司 Class A ISIN: CNE100003449 Shares Out.: Shares Outstanding: 416.294M¹ Shares Float: 250.435M² TV: TradingView: SZSE: 300676 SA: Stock Analysis: SHE: 300676 YF: Yahoo Finance: 300676.SZ GF: Google Finance: SHE: 300676 BA: Barron's: 300676 MS: Morningstar: XSHE: 300676	39.94 CNY	TV: TradingView: SZSE: 300676 SA: Stock Analysis: SHE: 300676 YF: Yahoo Finance: 300676.SZ GF: Google Finance: SHE: 300676 BA: Barron's: 300676 MS: Morningstar: XSHE: 300676

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About BGI Genomics Co., Ltd.

BGI Genomics Co., Ltd. engages in the provision of genomic sequencing services and proteomic services to academic institutions, pharmaceutical companies, health care providers and other organizations in China and internationally. The company offers DNA sequencing services covering whole genome sequencing, plant/animal whole genome sequencing, exome sequencing, de novo sequencing, and metagenomic sequencing; and mass spectrometry services, such as proteomic services and biologics characterization services. It also provides diagnostics and precision medicine, such as COVID-19 solutions, partnership opportunities, infectious diseases, and oncology services. The company was formerly known as Shenzhen BGI Medicine Co., Ltd. and changed its name to BGI Genomics Co., Ltd. in 2015. The company was founded in 1999 and is headquartered in Shenzhen, China. BGI Genomics Co., Ltd. operates as a subsidiary of BGI Group.

Similar Companies

Industry: Biotechnology (China)

Name	Market Cap (USD) diff.	PE	Country
WuXi Biologics (Cayman) Inc. SHEK: 2269	$17.45B 136.71B HKD 663%	25.3	China
CSPC Pharmaceutical Group Ltd. SHEK: 1093	$12.2B 95.58B HKD 434%	22.1	China
Sichuan Kelun Pharmaceutical Co., Ltd. SHE: 002422	$8.01B 54.23B CNY 251%	34.4	China
Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. SSE: 603392	$7.34B 49.69B CNY 221%	-	China
3SBio Inc. SHEK: 1530	$7.08B 55.5B HKD 210%	5.8	China
Hangzhou Tigermed Consulting Co., Ltd. SHE: 300347	$6.73B 45.52B CNY 194%	61.6	China

Industry: Biotechnology (Global)

Name	Market Cap (USD) diff.	PE	Country
Amgen Inc. NASDAQ: AMGN	$182.42B 8K%	23.9	United States
Gilead Sciences, Inc. NASDAQ: GILD	$159.92B 7K%	19.0	United States
argenx SE EBR: ARGX	$47.89B 41.39B EUR 2K%	39.9	Netherlands
Samsung Biologics Co.,Ltd. KRX: 207940	$44.92B 68.19T KRW 2K%	35.5	South Korea
CSL Ltd. ASX: CSL	$42.46B 60.27B AUD 2K%	29.3	Australia
Lonza Group AG SIX: LONN	$42.17B 33.71B CHF 2K%	37.2	Switzerland

chevron_leftBack